This is a working overview of MOD GRF 1-29, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-27 and is reviewed periodically as new material appears.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
=== Diagnosis === The diagnosis of liver disease is made by liver function tests, groups of blood tests, that can readily show the extent of liver damage. If infection is suspected, then other serological tests will be carried out. A physical examination of the liver can only reveal its size and any tenderness, and some form of imaging such as an ultrasound or CT scan may also be needed. Sometimes a liver biopsy will be necessary, and a tissue sample is taken through a needle inserted into the skin just below the rib cage. This procedure may be helped by a sonographer providing ultrasound guidance to an interventional radiologist.
isoelectronicity The phenomenon of two or more chemical species (atoms, molecules, ions, etc.) being composed of different elements but having the same number of valence electrons and the same structural arrangement (i.e. the same number of atoms with the same connectivity). Isoelectronic species typically show useful consistency and predictability in their chemical properties.
18 August – Researchers in Austria propose coupling an electron microscope to a trapped-ion quantum computer, allowing quantum information from successive electrons to be combined and potentially enabling high-resolution imaging with fewer electrons, reducing damage to sensitive samples. 19 August – Astronomers report the discovery of S301, the closest and fastest star yet observed orbiting Sagittarius A*, the supermassive black hole at the centre of the Milky Way. The star completes an orbit every 8.7 years and reaches about 25,000 km/s, or 8.5% of the speed of light, at its closest approach. Its unusually tight orbit may enable a direct measurement of Sagittarius A*'s spin within about a decade. 23 August – A review published in Global Challenges finds that no place on Earth is resilient to all of the major global catastrophic risks considered. Australia shows resilience across the widest range of scenarios, while geographic isolation, food self-sufficiency, high-quality governance and decentralisation emerge as recurring resilience factors. 26 August University College London reports that London neurosurgeons have performed the first AI-assisted brain surgery at the National Hospital for Neurology and Neurosurgery in a 48-year-old patient who was diagnosed with a brain tumour in 2024. The U.S. Food and Drug Administration approves the RAS inhibitor drug daraxonrasib as a treatment for metastatic pancreatic cancer. 30 August – NASA launches the flagship Nancy Grace Roman Space Telescope aboard a SpaceX Falcon Heavy rocket from the Kennedy Space Center in Florida.
Susan Weintraub is an American scientist. She is a professor at the University of Texas Health Science Center at San Antonio (UTHSCSA). She received a BS in chemistry from the University of Pennsylvania in 1967, MS in chemistry from Trinity University in 1970 and a PhD in biochemistry from UTHSCSA in 1979. She was the president of the American Society for Mass Spectrometry for the period of 2012-2014. In 2017 she was named a Fellow of the American Association for the Advancement of Science (AAAS), and Fellow of the American Society for Mass Spectrometry in 2025. She is an associate editor of the Journal of Proteome Research. Her research focuses on biomedical mass spectrometry where she used mass spectrometry in the early 1970s for quantitative analysis of brain neurochemicals. She has been director of the mass spectrometry core resource at UTHSCSA since 1979.
Sources: en.wikipedia.org
==== Manufacturing process ==== After ingredients are combined, they are placed in a tank at the end of a canning machine. From there, the mixture is forced through an opening and onto a metal sheet, forming a thickness of 8 to 12mm. Next, the mixture is heated to thoroughly cook the ingredients. Heating can be done through the means of ovens, microwaves or steam heating. The sheet containing a layer of feed is passed through the heat source that displays heat to the top and bottom of the tray, allowing the internal temperature to reach 77 degrees Celsius at a minimum. Once cooked, this mixture can be directly placed into cans to form a loaf or it can be cut into "meaty" pieces for chunks and gravy formulas.
=== Allenstein / Olsztyn Plebiscite Area === The Allied forces had to intervene here in 1919 to release imprisoned Masurians, who had tried to reach the Paris Conference. The president and British commissioner of the Inter-Allied Administrative and Plebiscite Commission for Allenstein was Ernest Rennie; the French commissioner was Couget; the Italian commissioner was Marquis Fracassi, a senator; and the Japanese commissioner was Marumo. The German government, under the Protocol's terms, was allowed to attach a delegate and sent Reichskommissar Wilhelm von Gayl, who had been in the service of the Interior Ministry before he was on the Inner Colonisation Committee. The local police forces were placed under the control of two British officers: Lieutenant-Colonel Bennet and Major David Deevis. Bennet reported that he regarded them as "well-disciplined and reliable". There was also a battalion from the Royal Irish Regiment and an Italian regiment stationed at Lyck (Ełk).
restriction enzyme Also restriction endonuclease, restriction exonuclease, or restrictase. An endonuclease or exonuclease enzyme that recognizes and cleaves a nucleic acid molecule into fragments at or near specific recognition sequences known as restriction sites by breaking the phosphodiester bonds of the nucleic acid backbone. Restriction enzymes are naturally occurring in many organisms, but are also routinely used for artificial modification of DNA in laboratory techniques such as restriction cloning.
=== Possible sainthood === On 2 September 2017 the Oxford Oratory, Tolkien's parish church during his time in Oxford, offered its first Mass for the intention of Tolkien's cause for beatification to be opened. A prayer was written for his cause.
In 1968, after experiencing HD in his wife's family, Dr. Milton Wexler was inspired to start the Hereditary Disease Foundation (HDF), with the aim of curing genetic illnesses by coordinating and supporting research. The foundation and Wexler's daughter, Nancy Wexler, were key parts of the research team in Venezuela which discovered the HD gene. At roughly the same time as the HDF formed, Marjorie Guthrie helped to found the committee to Combat Huntington's Disease (now the Huntington's Disease Society of America), after her husband, folk singer-songwriter Woody Guthrie died from complications of HD. Since then, support and research organizations have formed in many countries around the world and have helped to increase public awareness of HD. A number of these collaborate in umbrella organizations, like the International Huntington Association and the European HD network. Many support organizations hold an annual HD awareness event, some of which have been endorsed by their respective governments. For example, 6 June is designated "National Huntington's Disease Awareness Day" by the US Senate. Many organizations exist to support and inform those affected by HD, including the Huntington's Disease Association in the UK. The largest funder of research is provided by the Cure Huntington's Disease Initiative Foundation (CHDI).
Sources: en.wikipedia.org
=== Surgical drain technique === In extreme cases of intractable CSF leak, a surgical lumbar drain has been used. This procedure is believed to decrease spinal CSF volume while increasing intracranial CSF pressure and volume. This procedure restores normal intracranial CSF volume and pressure while promoting the healing of dural tears by lowering the pressure and volume in the dura. This procedure has led to positive results leading to relief of symptoms for up to one year.
=== Breaking the C-N bond and product release === The hydroxide ion joins with the carbon atom of the creatine's amidino group, creating a tetrahedral intermediate product. This intermediate product collapses and breaks the C-N bond, releasing urea. The remainder of the molecule rearranges to form sarcosine, and both products diffuse from the active site pocket.
=== 2015 === The index crossed the historical mark of 30,000 after repo rate cut announcement by RBI. The index plummeted by over 1,624.51 points on 24 August 2015, the then worst one-day point plunge in the index's history.
The superoxide ion, O−2 is generated in biological systems by reduction of molecular oxygen. It has an unpaired electron, so it behaves as a free radical. It is a powerful oxidizing agent. These properties render the superoxide ion very toxic and are deployed to advantage by phagocytes to kill invading microorganisms. Otherwise, the superoxide ion must be destroyed before it does unwanted damage in a cell. The superoxide dismutase enzymes perform this function very efficiently. The formal oxidation state of the oxygen atoms is −1⁄2. In solutions at neutral pH, the superoxide ion disproportionates to molecular oxygen and hydrogen peroxide.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.